Login
$EWTX
$43.68 -$2.25 (4.9%) Live

$EWTX 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

– Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain –

06 Aug 2026 8-K: Results of Operations and Financial Condition

– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –

13 Jul 2026 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

05 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Edgewise Therapeutics, Inc. (the “Company”) held its Annual Meeting of stockholders (the “Annual Meeting”) on June 4, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

01 Jun 2026 8-K: Entry into a Material Definitive Agreement

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

07 May 2026 8-K: Results of Operations and Financial Condition

Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications

26 Feb 2026 8-K: Results of Operations and Financial Condition

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

20 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

Boulder, Colo., (November 20, 2025) – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors....

10 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Certain exhibits and schedules have been omitted in accordance with Regulation S-K Item 601(a)(5). The registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the SEC upon its request, however the registr...

06 Nov 2025 8-K: Results of Operations and Financial Condition

– Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch –

07 Aug 2025 8-K: Results of Operations and Financial Condition

– Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies –

26 Jun 2025 8-K: Regulation FD Disclosure; Other Events

On June 26, 2025, Edgewise Therapeutics, Inc. (the “Company” or “Edgewise”) issued a press release announcing positive results in its sevasemten program for Becker and Duchenne muscular dystrophies. The press release is attached hereto a...

08 May 2025 8-K: Results of Operations and Financial Condition

– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) –

02 Apr 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”...

02 Apr 2025 8-K: Regulation FD Disclosure; Other Events

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

03 Mar 2025 8-K: Results of Operations and Financial Condition

– Completed enrollment of the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy (Becker) –

22 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

16 Dec 2024 8-K: Regulation FD Disclosure; Other Events

1 ©2024 Edgewise Therapeutics. All rights reserved. Sevasemten: Topline Results from the CANYON Phase 2 Trial in Becker December 16, 2024

07 Nov 2024 8-K: Results of Operations and Financial Condition

– On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024 –

12 Aug 2024 8-K: Departure/Election of Directors or Officers; Compensation

1.1 Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Comp...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support